DR HURVITZ: I think that those are going to be increasingly useful in deciding who to give prolonged therapy to. And BCI, so far, has addressed the: Do we do 5 additional years after 5 years of tamoxifen? And that is useful, but not as useful as it will be if they can use that sort of genomic data for this type of study design. And there are other studies ongoing that haven’t reported yet that will have a higher percentage of patients who did not receive 5 years of tamoxifen, so a higher percentage of patients who just went 5 years of AI versus 10 years of AI. And I think that’s going to be more clinically applicable to our patients. And doing genomic analyses to predict those patients who will be more likely to benefit is going to be really critical.
I was looking for – I’d be interested in seeing if PR negativity in this study would have predicted more benefit or less benefit and invasive lobular as opposed to invasive ductal. Those sort of simple things that don’t require a sophisticated biomarker analysis, I think, are also eagerly awaited.
T, AC